Ensysce Biosciences, Inc. Quarterly Operating Income (Loss) in USD from Q4 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Ensysce Biosciences, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q4 2017 to Q3 2024.
  • Ensysce Biosciences, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was $645K.
  • Ensysce Biosciences, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$6.31M, a 54.2% increase year-over-year.
  • Ensysce Biosciences, Inc. annual Operating Income (Loss) for 2023 was -$10.7M, a 55.8% increase from 2022.
  • Ensysce Biosciences, Inc. annual Operating Income (Loss) for 2022 was -$24.2M, a 21.9% decline from 2021.
  • Ensysce Biosciences, Inc. annual Operating Income (Loss) for 2021 was -$19.9M, a 1132% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$6.31M $645K +$3.35M Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$9.66M -$1.96M +$339K +14.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$10M -$1.84M +$718K +28% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 -$10.7M -$3.16M +$3.05M +49.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-15
Q3 2023 -$13.8M -$2.71M +$3.46M +56.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$17.2M -$2.29M +$4.76M +67.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$22M -$2.56M +$2.24M +46.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$24.2M -$6.2M -$4.15M -203% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-15
Q3 2022 -$20.1M -$6.16M +$10.7M +63.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$30.8M -$7.06M -$6.64M -1610% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 -$24.1M -$4.8M -$4.28M -816% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$19.9M -$2.05M -$1.61M -373% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 -$18.3M -$16.9M -$16.5M -4072% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$1.77M -$413K -$552K -397% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$1.22M -$524K +$391K +42.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$1.61M -$432K +$1.5M +77.6% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$3.11M -$405K +$180K +30.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$3.29M $139K +$765K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 -$4.05M -$915K -$726K -384% Jan 1, 2020 Mar 31, 2020 10-Q 2021-06-08
Q4 2019 -$3.33M -$1.93M -$1.7M -741% Oct 1, 2019 Dec 31, 2019 10-K/A 2021-06-08
Q3 2019 -$1.63M -$584K -$336K -135% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$1.29M -$626K -$314K -101% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 -$978K -$189K -$19K -11.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$959K -$229K -$82.7K -56.4% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-10
Q3 2018 -$877K -$248K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$312K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 -$170K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q4 2017 -$147K Sep 12, 2017 Dec 31, 2017 10-K/A 2019-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.